Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1055682 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR27446400_subreads.fastq.gz | Fastqsanger.gz | |||
| SRR27446401_subreads.fastq.gz | Fastqsanger.gz | |||
| SRR27446402_subreads.fastq.gz | Fastqsanger.gz | |||
| SRR27446403_subreads.fastq.gz | Fastqsanger.gz | |||
| SRR27446404_subreads.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 164 |
Similar Datasets
Project description:Cervical cancer is one of the most common cancers in women worldwide. The role of HPV in cervical cancer is well studied, however, the underlying mechanism promoting cervical tumorigenesis is still not fully understood. Recently, emodin was shown to induce cell cycle arrest, induction of differentiation, downregulation of TGF β signaling pathway and apoptosis in cervical cancer cell lines. Further, recent studies have shown the role of miRNAs in mediating abnormal regulatory mechanisms leading to the pathogenesis of cervical cancer and large scale miRNA profiling studies have examined the use of miRNAs as cervical cancer diagnostic markers. However, to date, there is no study being performed to analyze the changes in miRNAs following emodin treatment to determine whether emodin mediates its effects by regulating the expression of miRNAs. Therefore, the aim of the current study is to perform miRNA profiling in cervical cancer cells following emodin treatment and to analyze the roles of differentially expressed miRNAs in regulating the pathogenesis and treatment of cervical cancer.
2022-06-30 | GSE135699 | GEO
Project description:Comparable plasma lipid changes in patients with high-grade cervical intraepithelial neoplasia and patients with cervical cancer
2020-10-22 | MSV000086351 | GNPS
Project description:<p>This study aimed to highlight the relationships between vaginal microbiome composition, metabolic alterations, and gene expression changes during cervical cancer. Multi-omics analysis for the healthy (Z group), abortion (AB group), HPV infection (HP group), and cervical cancer group (CC group), qRT-PCR and cytotoxicity assays were used for validation. The CC group had the highest vaginal community diversity with decreased Lactobacillus and increase in anaerobic bacteria. In the HP group, Bifidobacteriales are obvious markers. Metabolomic analysis revealed changes in lipid metabolism pathways, the metabolic pathways of the AB and HP group were similar. Lactic acid and α-linolenic acid were negatively correlated with Anaerococcus and Porphyromonas. There were 8 up-regulated genes at HPV infection. Key upregulated genes in the CC group, including CCL2, CDKN1A, and IRF1, showed negative correlations with α-linolenic acid levels. The distinct microbial and metabolite patterns could facilitate in the diagnosis and treatment of cervical cancer. </p>
2025-11-26 | MTBLS10477 | MetaboLights
Project description:Cervical cancer is the second most common cancer in women worldwide. In addition to the important role played by HPV, the underlying mechanism promoting cervical tumorigenesis is complex and involves deregulation of key signaling pathways. Recently, role of miRNA mediated abnormal regulatory mechanisms is implicated in the pathogenesis of cervical cancer. Micro RNAs are regulatory, non‐coding RNAs about 21–23 nucleotides in length and effects the expression of a number of genes at the post‐transcriptional level. For the past few decades, role of curcumin in inhibiting the growth of cervical cancer and increasing the chemo and radio- sensistivity has been studied extensively. Interestingly, curcumin was shown to downregulate NF-κB, Wnt/β-catenin, TGF‐β and various other signaling pathways in cervical cancer cells. Although, a number of microarray studies have examined the use of miRNAs as cancer diagnostic markers, the regulation of miRNAs upon treatment with curcumin in cervical cancer cells has not been studied. The current study is aimed to perform miRNA profiling in cervical cancer cells following curcumin treatment and to study the role of miRNAs in regulating the different signaling pathways.
2022-06-30 | GSE134723 | GEO
Project description:Ulcerative colitis (UC) is a chronic inflammatory disease of the colon, associated with gut microbiota dysbiosis. While global studies have explored this link, region-specific microbial profiles remain underreported. This pilot study aimed to characterize and compare, for the first time, the gut microbiota of Lebanese UC patients and healthy controls using 16S rRNA gene sequencing (V3–V4 region). Fecal samples from 11 UC patients and 11 healthy individuals were analyzed. Alpha and beta diversity metrics were computed, and gut microbial composition was assessed across taxonomic levels. Statistical comparisons used Mann-Whitney and Fisher’s exact tests. UC patients showed significantly reduced microbial diversity based on Faith’s Phylogenetic Diversity and Shannon index (p < 0.05), though evenness was unaffected. Beta diversity also revealed significant group-level dissimilarities (p < 0.05). At the phylum level, Bacteroidota was elevated in UC, while Bacillota and Actinomycetota were reduced. Genera such as Ruminococcus, Fusicatenibacter, Mediterraneibacter, Eubacterium, and Coprococcus were depleted in UC. Faecalibacterium, commonly reduced in UC, showed no significant difference. This first analysis of gut microbiota in Lebanese UC patients reveals a distinct microbial signature that partially diverges from global trends, supporting the need for region-specific microbiome studies and personalized microbiota-targeted therapies.
2025-11-27 | GSE303706 | GEO
Project description:Cervical cancer remains a significant global health issue due to its high morbidity and mortality rates. Recently, Lactobacillus crispatus has been recognized for its crucial role in maintaining cervical health. While some studies have explored the use of L. crispatus to mitigate cervical cancer, the underlying mechanisms remain largely unknown. In this study, we employed non-targeted proteomics and metabolomics techniques to investigate how L. crispatus affects the growth of cervical cancer cells (SiHa) and normal cervical cells (Ect1/E6E7). Our findings indicated that the inhibitory effect of L. crispatus on SiHa cells was associated with various biological processes, notably the ferroptosis pathway. Specifically, L. crispatus was found to regulate the expression of proteins such as HMOX1, SLC39A14, VDAC2, ACSL4, and LPCAT3 by SiHa cells, which are closely related to ferroptosis. Additionally, it activated the TCA cycle in SiHa cells, leading to increased levels of reactive oxygen species (ROS) and lipid peroxides (LPO). These results reveal the therapeutic potential of L. crispatus in targeting the ferroptosis pathway for cervical cancer treatment, opening new avenues for research and therapy in cervical cancer.
2024-09-05 | MTBLS10498 | MetaboLights
Project description:Cervical cancer is the most common cancer among women worldwide, predominantly caused by human papillomavirus (HPV) subtypes, particularly HPV 16 and 18. Although it is largely preventable through vaccination and early detection, cervical cancer remains a significant health issue, particularly in low- and middle-income countries, mainly due to acquired chemoresistance. This study explores the therapeutic potential of deubiquitinating enzymes (DUBs), with a focus on ubiquitin-specific proteases (USPs), in combating oncogenesis in cervical cancer. Using the TCGA database, we assessed the prognostic relevance of USP14, revealing that elevated levels of this enzyme correlate with poorer overall and disease-free survival among cervical cancer patients. In-silico analysis of publicly available gene expression datasets also indicates a significant upregulation of USP14 in cervical cancer tumor tissues compared to their paired normal tissues. USP14 expression was analyzed at both the RNA and protein levels across various cervical cancer cell lines, followed by assays for proliferation, metastasis, and invasion to assess the impact of USP14 depletion. Elevated USP14 expression was observed in the cervical cancer cell lines, and inhibiting USP14 resulted in significant reductions in cell proliferation, metastasis, and invasion. A novel USP14 inhibitor, IU-1, produced similar results. Proteomic analysis indicated that the lactate transporter MCT-4, a crucial metabolic regulator, was dysregulated following USP14 alteration. Immunoprecipitation studies confirmed stable interactions between USP14 and MCT-4. Cycloheximide and Deubiquitination assays further demonstrated that USP14 modulates MCT-4 stability via deubiquitination at specific sites. Additionally, docking studies and molecular dynamics simulations illustrated the interaction between USP14 and MCT-4. Furthermore, the lactate shuttle was evaluated following USP14 inhibition, demonstrating the effect of MCT-4 inhibition on lactate production in cervical cancer cells. Immunohistochemical analysis of retrospective tissue samples assessed the expression of USP14 and MCT-4 and their correlation with patient prognosis. Collectively, our findings highlight the vital role of USP14 in the oncogenic and metabolic processes of cervical cancer, suggesting their potential as therapeutic targets. This research enhances the understanding of the molecular mechanisms driving cervical cancer progression and underscores the need for targeted therapeutic strategies.
2026-01-19 | PXD067901 | Pride